|Day's range||0.0700 - 0.0700|
As part of Le Chaînon's 90th anniversary, Organon Canada, a subsidiary of Organon (NYSE: OGN), a global women's health company, is announcing a contribution of $90,000 to help fund the mission of Le Chaînon and the creation of an in-house medical clinic.
JERSEY CITY, N.J., May 04, 2023--Organon Reports Results for the First Quarter Ended March 31, 2023
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JERSEY CITY, N.J., April 20, 2023--Organon To Report First Quarter and Host Conference Call on May 4, 2023
JERSEY CITY, N.J., March 07, 2023--Organon Launches "Her Plan is Her Power," a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
Organon Canada, a subsidiary of Organon (NYSE: OGN), a global women's health company, is excited to share that in line with National Employee Appreciation Day on March 3, it has received the Women in Governance Parity Certification SME 1. The WiG Parity Certification SME is a national benchmark recognizing notable organizations for their ongoing efforts and commitments to gender parity in the workplace. Through integrating numerous programs and policies across the organization, Organon Canada ha
For far too long, women's health issues have been underfunded, under researched and underserved. Leading up to International Women's Day on March 8, Organon Canada, a subsidiary of Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers and others – to consider the consequences of the growing health disparities that women are currently facing. In Canada, for the second consecutive year, the company
JERSEY CITY, N.J., February 16, 2023--Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2022.
JERSEY CITY, N.J., February 06, 2023--Organon (NYSE: OGN), a global women’s healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
JERSEY CITY, N.J., January 05, 2023--Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
JERSEY CITY, N.J., December 15, 2022--Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
JERSEY CITY, N.J., December 12, 2022--Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
JERSEY CITY, N.J., November 15, 2022--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST.
Organon (NYSE:OGN), a global women's healthcare company, today announced its formal commitment to FP2030 to help prevent 120 million unintended pregnancies by 2030. Recognizing the urgency of the crisis, Organon is taking action to scale access to contraceptive options for more than 100 million women in low- and middle-income countries (LMICs), in addition to strategic partnerships focused on education, training, advocacy and youth engagement.
Organon (NYSE: OGN), a global women's health company, today announced the availability and distribution of Ontruzant®, a biosimilar of Herceptin®, providing an additional treatment option for Canadian adults diagnosed with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC).1
Organon (NYSE: OGN), a global women's health company, is announcing the launch and product availability of Aybintio®, a biosimilar of Avastin®, providing a new treatment option for adult Canadian patients affected with certain aggressive forms of cancers, including metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), platinum-sensitive recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, platinum-resistant recur
JERSEY CITY, N.J., November 03, 2022--Organon reports results for the third quarter ended September 30, 2022
JERSEY CITY, N.J., October 20, 2022--Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022
On World Contraception Day (September 26), Organon (NYSE: OGN), a global women's health company, is launching Act with Her, a multi-faceted approach to help tackle the global health issue of unintended pregnancies (UIPs) and to improve access to contraception. Organon is proud to support the Society of Obstetricians and Gynaecologists of Canada (SOGC) to reinforce the importance of education and awareness in reducing unplanned pregnancies in Canada through roundtable discussions. In addition, Or
INCHEON, Korea & JERSEY CITY, N.J., August 17, 2022--Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
JERSEY CITY, N.J., August 04, 2022--Organon reports results for the second quarter ended June 30, 2022
JERSEY CITY, N.J., July 28, 2022--Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
JERSEY CITY, N.J., July 21, 2022--Organon will release its second quarter 2022 financial results on 8/4/22, prior to the company’s webcast and call scheduled for 8:30 a.m. EDT.
JERSEY CITY, N.J., June 13, 2022--Organon announces first biosimilars business deal with a global license agreement with Henlius.